高血壓 高尿酸 慢性腎病 胰島素 https://2019medicinenote.blogspot.com/2019/12/blog-post_57.html . 糖尿病相關筆記~目錄 https://2019medicinenote.blogspot.com/2020/01/blog-post_4.html

2023年7月14日 星期五

112-06-30 法務部修正「公職人員財產申報表填表說明」部分規定,並自112年9月1日生效,請查照並轉知公職人員財產申報義務人。

主旨:法務部修正「公職人員財產申報表填表說明」部分規定,並自112年9月1日生效,請查照並轉知公職人員財產申報義務人。
說明:
一、依本府112年7月5日新北府政四字第1121266620號函轉法務部112年6月30日法廉字第11205002470號及第11205002471號函辦理(附件1~3)。
二、法務部業修正「公職人員財產申報表填表說明」部分規定,修正內容主要如下,並自112年9月1日生效:
刪除基本資料-國籍欄位。
增列「虛擬資產」為應申報項目,內容包括名稱、所有人、單位數(顆/件)、存放機構(錢包廠商)、帳戶名稱、取得(投資)原因及新臺幣或折合新臺幣交易價額等資訊。
修正保險項目應申報之內容,有關「保險金額」、「外幣幣別」、「累積已繳保險費外幣總額」、「累積已繳保險費折合新臺幣總額」等資訊刪除,並增加「備註」欄位。
三、檢附公職人員財產申報表填表說明(含修正總說明、修正對照表)、公職人員財產申報表「基本資料」、「保險」、「虛擬資產」填表範例各1份(如附件4~8) 財產申報表填寫說明





2008-08-20 11:05 疾管院區顏院長慕庸協助修訂登革熱速成寶典(醫療人員篇)

疾管院區顏院長慕庸協助修訂登革熱速成寶典(醫療人員篇)

2008-08-16 因應北部出現登革熱病例. 顏院長協助修訂速成指引. 
先貼一段當時的新聞. 下面則是重點整理. 

本土登革熱 北市驚爆首例
更新日期:2008/08/16 08:00 記者邱瓊玉/台北報導
台北市出現首起本土性登革熱病例。台北市衛生局表示,日前接獲通報四名疑似登革熱病例,其中兩人為夫妻,且近期沒有出國旅遊,十三日確診是感染本土性登革熱;兩人目前均住院,病房也掛蚊帳。
衛生局統計顯示,北市今年共接獲六十四起登革熱通報病例,確診卅二例,卅例為境外移入,剛確認的兩例是本土性個案;今年相較於去年同時期接獲通報四十二病例,確診十三例的數據高出許多,加上今年首度出現本土性登革熱,讓北市進入防疫安全管理紅燈警訊期。
為避免疫情擴散,環保局已到個案住家環境噴藥,衛生局排定今、明兩天到病患住家半徑五十公尺內進行室內噴藥,並對附近十個里進行戶外噴藥。
北市衛生局主任秘書陳正誠表示,這對夫婦家住士林社子永倫里,日前因身體不舒服到醫院就診,由於出現與登革熱相似症狀,醫生對兩人抽血檢驗,確認感染登革熱。
五十七歲的丈夫目前在桃園工作,五十三歲的妻子是家庭主婦,七月曾被蚊蟲叮咬,確認均沒有出國紀錄,也未到中南部遊玩,因此排除為市外移入的案例;同時發現,他們居家的積水容器中,有孑孓孳生,將加強環境清潔。
陳正誠表示,為避免登革熱疫情擴散,接獲通報當天,就完成個案居家的孳生源及病媒蚊調查,並安排環保局到病患住家周圍及工作地點進行環境噴藥及滅蚊工作。
十三日起,開始辦理個案住家附近周圍半徑一百公尺內的住戶登革熱衛教宣導,並對附近居民全面抽血檢驗,訪查個案住家附近診所,將病患發病前一個月內,曾到診所就醫並具有感冒症狀的患者全面造冊,列管追蹤,釐清感染源。

台北教育大學環境教育與資源研究所助理教授黃基森表示,一旦健康的蚊子叮咬過患者後,終其一生都會有傳染登革熱病毒的能力,假使這些病媒蚊再去叮其他健康人體,就會使罹患登革熱的人數變多。
黃基森表示,北部登革熱病媒蚊為白線斑蚊,和埃及斑蚊不同的是,白線斑蚊活動範圍不限於室內,野外也常可看到白線斑蚊的蹤跡,防治範圍相對較大;建議民眾除加強積水容器的清除,外出遊玩最好做好防蚊措施,避免被蚊蟲叮咬。


登革熱速成寶典-(醫療人員篇)(顏院長慕庸修訂版)
醫療人員處理登革熱病例教戰守則

一、 病人在什麼樣狀況及臨床症狀要懷疑是感染登革熱?
由於目前為臺北市本土性登革熱防疫動員期,因此建議醫護同仁看診時,除了例行性發燒病人「TOCC旅遊史、接觸史、群聚史」之問診外,台北市大都會區自即日起至97年9月9日宣佈疫情結束止,所有發燒病人(包含不具旅遊使者)宜注意是否有有頭痛、全身酸痛、關節疼痛、眼窩後疼痛、無力、吃不下東西、出疹子或出血的病人,特別是有出血現象、白血球降低、血小板下降十萬以下,診斷上均需要考慮登革熱。

二、發現疑似登革熱個案應如何處置?
發現疑似登革熱個案應馬上通報衛生所,並抽血送驗或通知衛生所採血送驗。


三、對於高度懷疑或確診登革熱個案應如何處置?
高度懷疑或確診登革熱個案,應即轉診至大型有治療經驗的醫院治療。

四、對疑似登革熱病人應該做哪些衛教的工作?
對於診斷為疑似登革熱病例,應向個案衛教避免再被斑蚊叮咬,清除住家附近孳生源,並預告衛生、環保單位會到住處做疫調和消毒的工作,取得病人同意。

五、什麼樣的情況即可診斷為登革出血熱?
登革出血熱和典型登革熱初期的症狀相似。當發燒3∼4 天後,病人有出血現象、血小板下降十萬以下、血球比容上升20%以上和血漿滲出現象(肋膜積水或腹水)時,即診斷為登革出血熱。

六、登革出血熱大多發生在什麼時間?要向家屬或病人做哪些吩咐?
登革出血熱併發出血和休克,大約在退燒當天或隔天,臨床症狀快好起來的時候,所以,醫師特別要向病人和家屬吩咐,此時若有心胸悶、冒冷汗、手腳冰冷、臉色蒼白等血壓下降現象,住院病人馬上要告知醫護人員;門診病人馬上要再去看醫生。

七、疑似登革熱檢查、治療和給藥時應該注意什麼?
避免做侵襲性檢查、治療或開刀。發燒時給予Acetaminophen,避免用類固醇、Aspirin,或NSAID 類的藥物。不要在點滴中加Aspirin,來作為鎮痛解熱藥。住院病人,要確定病房無病媒蚊,最好掛蚊帳以避免成為感染源。

八、有登革熱/登革出血熱病人的照顧或治療問題時,可向誰尋求諮詢?
有關登革熱/登革出血熱的治療或通報等問題,可向疾病管制局(0800-024582)、上網(http://www.cdc.gov.tw)查詢,或參閱該局出版之「登革熱/登革出血熱,臨床症狀、診斷與治療」手冊

2023年7月13日 星期四

護理人員法第三十七條修正案

中華民國一百十二年六月二十一日總統華總一義字第 11200051851號令修正公布第 37 條條文

第 37 條
未取得護理人員資格,執行護理人員業務者,處三年以下有期徒刑,得併科新臺幣三萬元以上十五萬元以下罰金。但在護理人員指導下實習之高級護理職業以上學校之學生或畢業生,不在此限。
僱用前項未取得護理人員資格者,處新臺幣一萬五千元以上十五萬元以下罰鍰。

[2023-05-30]YAHOO新聞-打擊密護!立院三讀修正護理人員法 無照執業最重關3年-

具護理專業的民進黨立委陳靜敏指出,本次修法加入相關刑責,並適度提升罰鍰,盼透過修法來遏止無照行為,藉此捍衛護理專業,提升全民照護品質。她指出,執行醫療業務的場域,聘用經國家考試通過的人員,是民眾就醫的最基本保障,醫師法、心理師法、職能治療師法、物理治療師法等,都是針對沒有取得合法資格職業的處有相關刑責,盼修法通過後能落實共同打擊密護,捍衛全民健康。

三讀條文指出,未取得護理人員資格,執行護理人員業務者,處3年以下有期徒刑,得併科3萬元以上、15萬元以下罰金。但在護理人員指導下實習的高級護理職業以上學校的學生或畢業生,不在此限;僱用前項未取得護理人員資格者,處1萬5000元以上、15萬元以下罰鍰。

此外,由於醫師公會全國聯合會憂心修法通過後,恐使現有醫護人力變得緊繃,今日立法院會也通過附帶決議,要求本法施行應考量全國各地醫護人力現況,請衛福部調查實際人力需求,強化教考用一致,確保護理發展及民眾醫療照護與長照服務品質。

2023年7月12日 星期三

高齡友善健康照護機構認證-高齡定義

高齡友善健康照護機構認證的高齡定義. 在不同醫療院所並不完全相同. 
可各自定義. 例如 85歲(含)以上. 作為優先看診條件. 
看診順序可參考台大的做法: 
順號→順號→85歲以上高齡(敬老)→檢後再診號→過號→特殊狀況號,安排叫號順序

台北榮總則將看診與掛號的優先條件區隔開來. 且限制對象為榮民及警消空勤人員. 75歲以上就可優先掛號. 但 85 歲以上才能優先看診. 一般民眾不適用這個條件. 

[112-03-17]衛生福利部國民健康署-112 年高齡友善健康照護機構認證-作業說明(衛生所版)
裡面並未對高齡做出定義

國泰醫院--- 高齡及特殊族群友善服務
特殊族群對象定義:
高齡(85歲以上)、身障者(肢體、視、聽覺)、外語人士。
高齡(85歲以上)作法:
專設11號「愛心掛號批價櫃檯」,提供長者個別化服務。
門診「優先看診服務」
藥局及檢驗抽血優先服務
大廳增設自助掛號機/慢箋取號機,由同仁或志工協助長者操作,增加方便電子化掛號服務。
針對高齡、獨自就醫(弱勢)長者,由志工走動式陪伴引導服務。


臺大醫院
107年12月31日已完成兒童醫院小兒科門診區(1~4F)、乳房醫學門診,後續108年1月14日將進行外科一、二診區、精神科門診上線;此系統主要功能提供病患透過健保IC卡自動報到就診後、相關就診資訊可透過資訊系統依本院門診病人就診順序規範:
順號→順號→85歲以上高齡(敬老)→檢後再診號→過號→特殊狀況號,安排叫號順序

台北榮總
[2021-10-25]台北榮總-高齡長者綠色通道服務
本院實施高齡長者綠色通道服務:
一、85歲以上榮民、警察消防海巡空勤人員優先看診。
二、75歲以上榮民、警察消防海巡空勤人員優先掛號、批價及簽床。






















[2011-10-27]由活躍老化觀點談國民健康新願景 陳姿伶 衛生署國民健康局成人及中老年保健組組長



2014-11-04
高齡友善健康照護機構,守護長者健康 -高齡友善健康照機構推動成果發表會
節錄
落實高齡友善政策,營造組織文化
臺北榮民總醫院就醫病患超過半數為65歲以上長者,有感於高齡者健康照護的複雜性與必要性,自民國93年起明定發展高齡醫學為重要目標策略,整合各領域專業人才及資源,致力推展高齡醫學門診、住院服務、中期照護、培育專才及研究創新。

節錄
新光醫院自88年起即開始推動長者照護之服務,102年宣誓為「高齡友善年」,全院同仁致力於高齡友善環境建置及服務品質的改善。從志工或為您服務人員陪同就醫,為長者提供無障礙的就醫環境,設立高齡友善整合門診,建立80歲以上長者無縫式就醫優先服務




2023年7月10日 星期一

衛教資料

糖尿病衛教學會臉書-抽血報告-糖尿病必知檢驗數值

新光醫院營養科-營養衛教內容非常多.
心臟衰竭飲食原則
口腔癌術前飲食原則
大腸直腸癌術後飲食原則
全流質飲食原則
血液透析飲食原則
低油飲食原則
低普林飲食原則
低渣飲食原則
吞嚥困難飲食原則
肝癌飲食原則
肝臟疾病飲食原則
乳癌術後營養飲食原則
使用抗凝血劑飲食原則
放化療期間之飲食原則
肺癌術後飲食原則
胃術後飲食原則
胃癌術後飲食原則
限鈉飲食原則
食道癌術後飲食原則
高三酸甘油脂血症飲食原則
高脂血症飲食原則
鈣質補充飲食原則
溫和飲食原則
慢性阻塞性肺病飲食原則
慢性腎臟病飲食原則
管灌配方保存方式
燒燙傷飲食原則
糖尿病飲食原則
癌症治療飲食原則
簡易食物代換表
體重控制飲食原則






2023年7月4日 星期二

急性複雜性(較嚴重的)泌尿道感染抗生素選擇 Antibiotics choice of acute complicated UTI

2023-01-02 19:15 這篇的內容太龐大. 將一部分另外做筆記
Asymptomatic bacteriuria 無症狀菌尿症


2018-09-21 UPTODATE 建議
複雜性UTI診斷: 
Diagnosis — The diagnosis of acute complicated UTI is made in the following clinical scenarios:
1. 發燒. 或其他全身性症狀. 畏寒. 神智改變.
2. 軀幹疼痛. 懷疑腎臟發炎. 通常伴隨發燒或其他膀胱炎症狀. CT可看到腎臟周圍發炎. 有時候伴隨膿瘍. 但CT正常無法排除輕微腎盂腎炎.
3. 發燒或敗血症. 排除其他感染源.. 如果沒有膿尿. 不太可能是複雜性 UTI.
●Symptoms of cystitis (dysuria, urinary urgency, and/or urinary frequency) along with fever (>99.9ºF/37.7ºC) or other signs or symptoms of systemic illness, such as chills, rigors 嚴格.嚴酷, or acute mental status changes. In such cases, pyuria and bacteriuria support the diagnosis.
●Flank pain and/or costovertebral angle tenderness in the setting of pyuria and bacteriuria. This is suggestive of pyelonephritis. Fever and typical symptoms of cystitis are usually present, but their absence does not rule out the diagnosis. CT findings that support the diagnosis include low attenuation extending to the renal capsule on contrast enhancement with or without swelling and complications such as renal abscesses. However, a normal CT does not rule out the possibility of mild pyelonephritis.
●Fever or sepsis without localizing symptoms in the setting of pyuria and bacteriuria may be attributed to UTI if other causes have been ruled out. Careful clinical assessment is necessary. The diagnosis of is unlikely if pyuria is absent.
因複雜性 UTI 住院病患. 依據病患是否可能有多重抗藥性細菌的危險因子, 決定使用的藥物種類. 依照流程圖, 先評估病患是否需要收 ICU. 是否敗血症. 是否尿道阻塞.
再來評估是否有抗藥性: 尿培養出MDR細菌. 曾經使用 FQ. BAKTAR. 廣效效 BETA-LACTAM. 三代以上的頭孢素抗生素. 曾經去高抗藥性地區旅行. (印度.以色列. 西班牙. 墨西哥). 如果以上皆否. 可選擇
CEFTRIAXONE 1gm QD.
tazocin 3.375g Q6H 或 TAZOCIN 4.5g Q6H
CIPROXIN 400 MG Q12H IV.
CIPROXIN 500 mg PO BID
CIPROXIN 1000 mg EXTENDED RELEASE QD.
CRAVIT 750 mg IV QD.
CRAVIT 750 mg PO QD.
如果懷疑是抗藥性的 Gram positive infection. 加入下列一種
VANCOMYCIN 15mg/kg. Q12H
DAPTOMYCIN,UVOM 6mg/kg QD
LINEZOLID 600 mg IV OR oral Q12H

Other hospitalized patients — For patients who are hospitalized for acute complicated UTI but are not critically ill and do not have suspected urinary tract obstruction, our approach to empiric antimicrobial regimen selection depends on the risk for infection with multidrug-resistant gram-negative organisms (algorithm 1).
●No risk factors for infection with a multidrug-resistant gram-negative organism (table 2) – For these patients, we favor ceftriaxone (1 gram IV once daily) or piperacillin-tazobactam (3.375 grams IV every six hours) for parenteral treatment because of their safety profile and narrow spectrum compared with other parenteral agents. Oral or parenteral fluoroquinolones (ciprofloxacin or levofloxacin) are also reasonable alternatives if the patient has not had a urinary isolate resistant to fluoroquinolones in the prior three months and the community prevalence of E. coli fluoroquinolone resistance is not known to be higher than 10 percent.
Concern for particular pathogens should further inform the choice between these options. If Enterococcus or Staphylococcus species are suspected (eg, because of prior urinary isolates or gram-positive cocci on a current urine Gram stain), piperacillin-tazobactam is preferred because it has activity against these organisms (if the patient cannot use piperacillin-tazobactam because of allergies or otherwise, vancomycin plus one of the other gram-negative agents can be used). If drug-resistant gram-positive organisms are suspected because of previous urinary isolates or other risk factors, vancomycin (for MRSA) or linezolid or daptomycin (for vancomycin-resistant Enterococcus [VRE]) should be added. If there is a risk of P. aeruginosa (eg, because of prior urinary isolates or febrile neutropenia), piperacillin-tazobactam at a higher dose (4.5 grams IV every eight hours) or a fluoroquinolone should be chosen. Other antipseudomonal agents that can be used include cefepime (2 grams IV every eight hours) and ceftazidime (2 grams IV every eight hours).
●At least one risk factor for infection with a multidrug-resistant gram-negative organism (table 2) – For these patients, we favor empiric treatment with an antipseudomonal carbapenem (imipenem 500 mg IV every six hours, meropenem 1 gram IV every eight hours, or doripenem 500 mg IV every eight hours).
Concern for particular pathogens should further inform regimen selection. If Enterococcus species or MRSA are suspected (eg, because of prior urinary isolates or gram-positive cocci on a current urine Gram stain), we add vancomycin (for MRSA) or daptomycin or linezolid (for vancomycin-resistant Enterococcus [VRE]).
Advanced cephalosporin or carbapenem combinations with beta-lactamase inhibitors (such as ceftazidime-avibactam, ceftolozane-tazobactam, and meropenem-vaborbactam) also have activity against some ESBL-producing and multidrug-resistant P. aeruginosa isolates and are effective for acute complicated UTI [29-31], but because of cost and antimicrobial stewardship concerns, they should only be used in select cases of highly resistant infections. If carbapenem resistance is suspected based on prior susceptibility testing results, an infectious diseases consult should be obtained.
Results of urine culture and susceptibility testing should be followed to ensure that the chosen empiric antimicrobial regimen is appropriate and to guide selection of definitive therapy.
complicated cystitis UTI 抗生素選擇











treatment of UTI adult dose recommendation. 治療泌尿道感染 成人建議劑量.










泌尿道感染應該使用多少天的抗生素





哪些情況需考慮作尿液培養(eMedicine連結)
Urine Culture


Urine culture remains the criterion standard for the diagnosis of UTI. Collected urine should be sent for culture immediately; if not, it should be refrigerated at 4°C. Two culture techniques (dip slide, agar) are widely used and accurate.
The 2010 Infectious Disease Society of America (IDSA) consensus limits for cystitis and pyelonephritis in women are more than 1000 colony-forming units (CFU)/mL and more than 10,000 CFU/mL, respectively, for clean-catch midstream urine specimens. Historically, the definition of UTI was based on the finding at culture of 100,000 CFU/mL of a single organism. However, this misses up to 50% of symptomatic infections, so the lower colony rate of greater than 1000 CFU/mL is now accepted. [22]
The definition of asymptomatic bacteriuria still uses the historical threshold. Asymptomatic bacteruria in a female is defined as a urine culture (clean-catch or catheterized specimen) growing greater than 100,000 CFU/mL in an asymptomatic individual.
Note that any amount of uropathogen grown in culture from a suprapubic aspirate should be considered evidence of a UTI. Approximately 40% of patients with perinephric abscesses have sterile urine cultures.
An uncomplicated UTI (cystitis) does not require a urine culture unless the woman has experienced a failure of empiric therapy. Obtain a urine culture in patients suspected of having an upper UTI or a complicated UTI, as well in those in whom initial treatment fails.
If the patient has had a UTI within the last month, relapse is probably caused by the same organism. Relapse represents treatment failure. Reinfection occurs in 1-6 months and usually is due to a different organism (or serotype of the same organism). Obtain a urine culture for patients who are reinfected.
If a Gram stain of an uncentrifuged, clean-catch, midstream urine specimen reveals the presence of 1 bacterium per oil-immersion field, it represents 10,000 bacteria/mL of urine. A specimen (5 mL) that has been centrifuged for 5 minutes at 2000 rpm and examined under high power after Gram staining will identify lower numbers. In general, a Gram stain has a sensitivity of 90% and a specificity of 88%.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875701/
Urine culture
The diagnosis of UTI from simple cystitis to complicated pyelonephritis with sepsis can be established with absolute certainty only by cultures of urine. The major indications for urine cultures are:
Patients with symptoms or signs of UTIs;
Follow-up of recently treated UTI;
Removal of indwelling urinary catheter;
Screening for asymptomatic bacteriuria during pregnancy; and
Patients with obstructive uropathy and stasis, before instrumentation.
Urine specimens must be cultured promptly within 2h or can be preserved by refrigeration or a suitable chemical additive (boric acid sodium formate). Acceptable methods of collection are:
Midstream urine after careful washing;
Urine obtained by single catheterization;
Urine obtained by supra pubic needle aspiration; and
Sterile needle aspiration of urine from the tube of a closed catheter drainage system.
Results of cultures depend on the clinical setting in which bacteriuria occurs. For example, E. coli are found in the urine of 80-90% of patients with acute uncomplicated cystitis and acute uncomplicated pyelonephritis. Many patients with staghorn calculi harbour urea-splitting proteus organisms in their urine. Klebsiella, Pseudomonas and Enterobacter infections are commonly acquired in the hospital. The presence of Staphylococcus aureus often is a clue to concomitant Staphylococcal bacteremia, unless an underlying risk factor exists.
Micro-organisms in young men are similar to the organisms that cause uncomplicated infections in women. Enterococci and coagulase-negative staphylococci are more common in elderly men; most likely representing recent instrumentation or catheterization. C. albicans is rarely encountered except in patients with indwelling catheters, nosocomial UTIs or relapsing infections after multiple courses of antibiotics. Although the likely organism and usual susceptible patterns are sufficient to guide initial empiric therapy of uncomplicated UTI, adequate treatment of acute bacterial pyelonephritis and complicated UTIs necessitates precise therapy based on isolation of the causative bacterium and its antimicrobial susceptibility.[13]



Significant bacteriuria
It is defined as the presence of 100 000 or more colony forming units (CFU) per ml of urine. This Kass[1] criteria has been questioned and bacterial counts of 102 or more organism per ml particularly when accompanied by pyuria (>10 wbc/mm3) provide impressive evidence of urinary tract infection in symptomatic young women.[2] The Infectious Disease Society of America (IDSA) gave a slightly more relaxed consensus definition requiring 103 organisms per ml to diagnose cystitis and 104 per ml for pyelonephritis.[3]
Clinical setting
Asymptomatic bacteriuria 無症狀菌尿症
This is especially common in women as evidenced by a minimum prevalence of 2-4% in young and 10% in elderly women. The cumulative prevalence of asymptomatic bacteriuria in women increases about 1% per decade throughout life regardless of ethnicity and geographic locations.

In contrast to women, the occurrence of asymptomatic bacteriuria in men is rare until after 55 years of age, at which time the prevalence increases per decade and approaches the rate in elderly women. Prostatic hypertrophy and increased likelihood of instrumentation account for the bacteriuria in older men.[11]

Differences between men and women in the rates of bacteriuria have been attributed to the shorter female urethra and its proximity to the vagina and rectal mucosa and their abundant microbial flora.



Clinical Features
Acute urethral syndrome
The cardinal symptoms of frequency and dysuria occur in more than 90% of ambulatory patients with acute genitourinary tract infections. However, one-third to one- half of all these patients do not have significant bacteriuria, although most have pyuria. These patients have acute urethral syndrome which can mimic both bladder and renal infections. Vaginitis, urethritis and prostatitis are common causes of the acute urethral syndrome.[14]

Vaginitis
The presence of an abnormal vaginal discharge (leucorrhoea) and irritation makes vaginitis the likely cause of dysuria unless a concomitant UTI can be confirmed by culture. Candida albicans, the most common specific cause of vaginitis, can be demonstrated by culture or by finding yeast cells in a gram-stained smear of vaginal secretions or in a saline preparation with the addition of potassium hydroxide.

Trichomoniasis can be documented with a saline preparation that shows the motile protozoa of trichomonas vaginitis. Generally, nonspecific vaginitis is associated with gardenerella vaginitis. A clue of this diagnosis is the presence of many small Gram-negative bacilli that adhere to vaginal epithelial cells.

Urethritis
Acute urinary frequency, dysuria and pyuria in the absence of vaginal symptoms favor the diagnosis of urethritis or UTI. Chlamydia trachomatis is the common cause of the acute urethral syndrome in women and of nonspecific urethritis in men. Neisseria gonorrhoeae is an important cause of urethritis and dysuria. Herpes simplex virus, usually type 2, is another sexually transmitted agent that can cause severe dysuria through ulceration in close proximity to the urethral orifice. The diagnosis of Herpes progenitalis can be confirmed by finding giant multinucleated transformed cells in epidermal scrapings stained with Wright's stain (Tzanck Smear), by isolating the virus in tissue cultures or by direct fluorescent antibody test.

Prostatitis
Prostatitis is a common problem in men that causes dysuria and urinary frequency in middle-aged and younger men more frequently than urinary tract infection do. Prostate syndromes have classically been divided into four clinical entities

Acute bacterial prostatitis
Chronic bacterial prostatitis
Nonbacterial prostatitis
Prostatodynia
Recently, consensus classification of prostatitis syndromes has come up. This classification includes four categories and two subcategories.[15]

Acute bacterial prostatitis;
Chronic bacterial prostatitis;
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS);
Asymptomatic inflammatory prostatitis.
CP/CPPS has been divided in to two sub-categories:
Inflammatory CP/CPPS; and
Non- inflammatory CP/CPPS
Acute bacterial prostatitis: The patient often appears acutely ill with the sudden onset of chills and fever, urinary frequency and urgency, dysuria, perineal and low back pain and constitutional symptoms. Rectal examination should be avoided because of the risk of precipitating sepsis, but may disclose a tender, hot and swollen prostate. Microscopic examination of the urine usually displays numerous white cells. Urine culture is usually positive for enteric Gram-negative bacteria and Gram-positive bacteria staphylococci and enterococci are less frequently isolated.

Chronic bacterial prostatitis: Relapsing UTIs is a hallmark of chronic bacterial prostatitis. Urinary frequency, dysuria, nocturia and low back and perineal pain are the usual symptoms, although patients may have a minimum of symptoms between UTIs. The patient is often afebrile, does not appear acutely ill, and may have an unremarkable prostate examination. Initially, there is a negative midstream urine examination and culture but after prostate massage, the urine is positive for white blood cells and culture grows a uropathogen.

Nonbacterial prostatitis: This is the most common form of chronic prostatitis. It mimics chronic bacterial prostatitis clinically and displays inflammatory cells on post-prostate massage specimens. However, a bacteriological culture of urine and prostatic secretions are sterile. The etiology is unknown, but some evidence exists for an infectious cause involving organisms that are difficult to culture.

Prostatodynia: This has also been referred to as chronic noninflammatory prostatitis. Clinically, it presents with symptoms similar to other forms of chronic prostatitis. It is distinguished by the absence of inflammatory cells or uropathogens from all specimens.

Chronic prostatitis/chronic pelvic pain syndrome: The traditional classification suggested that the prostate was the cause for some patients (nonbacterial prostatitis), whereas other problems were responsible in others (prostatodynia). The characteristic symptoms for either group were very poorly defined. CP/ CPPS acknowledges the central role of pain complaints in the syndrome. Also there is inherent recognition that the prostate gland may not be responsible for every patient's symptoms. Its two subcategories are as follows:

Inflammatory CP/CPPS: The consensus classification considers symptomatic patients without bacteriuria but who have inflammation in their expressed prostate secretions, their voided bladder 3 (VB3) or their semen fluid analysis (SFA), to have inflammatory CP/CPPS.
Noninflammatory CP/CPPS: Patients without inflammation in their expressed prostate secretions, their voided bladder 3 (VB3) or their semen fluid analysis (SFA) are considered to have noninflammatory CP/CPPS.
Asymptomatic inflammatory prostatitis: The consensus classification also includes a category for patients with objective evidence of prostatic inflammation noted during histological evaluation of prostatic tissue. This diagnosis commonly occurs in patients who have inflammation documented during evaluation of other urologic conditions, for example, prostatic evaluated for a raised prostate-specific antigen. Another example is seminal fluid inflammation noted during evaluation from an infertile couple. The long-term consequences of such asymptomatic inflammation are unknown. Further, only limited data are available on the relative merits of antimicrobial or other therapies for such asymptomatic patients.

Urinary tract infection: Despite the mimicking syndromes, a presumptive diagnosis of infections of urinary tract can be established economically by analyzing urine in patients with characteristic signs and symptoms. Acute uncomplicated UTIs mainly occur in women of child-bearing age. The presenting features are only suggestive of the site of infection. Patients with bacterial cystourethritis, as distinct from urethritis caused by sexually transmitted disease (STD) pathogens, will have prior episodes and experienced symptoms for less than one week and will experience suprapubic pain


女性單純UTI口服抗生素選擇

 女性單純UTI口服抗生素選擇
2
023-02-02 08:36AM 目前建議第一線用藥還是選 baktar. 而 cefa 可做為第二線用藥
如果局部地區的baktar抗藥性超過 20%, 就別選 baktar. 
from uptodate 

Trimethoprim-sulfamethoxazole – Dosed as 
one double-strength tablet (160/800 mg) orally twice daily for three days. Randomized trials suggest a 79 to 100 percent clinical cure rate with a three- to seven-day regimen [48,56-58]. Empiric trimethoprim-sulfamethoxazole should be avoided if the regional prevalence of resistance is known to exceed 20 percent [29,30]. In some regions, trimethoprim (100 mg twice daily for three days) is used in place of trimethoprim-sulfamethoxazole and is considered equivalent [59].

關於台灣的大腸桿菌對 baktar 抗藥性問題. 沒有搜尋到直接的研究. 在2018年台中榮總婦產科蔡青倍醫師的文章. 有提到抗藥性問題. cefa 和 baktar 都有抗藥性的憂慮 . 

女性單純膀胱炎 (cystitis/UTI) 通常開
BAKTAR 400mg BID * 3 days or 
CEFA 500mg Q6H * 3-7 days
[參考資料]反反覆覆的婦女泌尿道感染 [更新日期 2018/10/8 11:30:44]

Trimethoprim-Sulfamethzazole(TMP-SMX)160/800mg. ㄧ天兩次服用三天廣效性。然而目前研究顯示
對TMP-SMX有抗藥性的大腸桿菌越來越多(>17%),但由於此藥便宜,且濫用Fluoroquinolone會衍生出更多抗藥性的問題,故目前此藥還是泌尿道感染的首選藥物。

Cefalexin 250mg 一天四次服用7-10天.抗菌效果較廣泛,但其抗藥性也是與日俱增,且因其廣效性,所以可能破壞人體的正常菌叢,造成不必要的念珠菌感染,但其可以當成孕婦泌尿道感染的第二線用藥

2023-02-02 09:02AM

美國感染症學會的單純泌尿道感染指引(連結在此), 最近更新日期是 2011年3月. 已經11年沒有改版了. 

JOURNAL ARTICLE GUIDELINES-International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases .
Clinical Infectious Diseases, Volume 52, Issue 5, 1 March 2011, Pages e103–e120, https://doi.org/10.1093/cid/ciq257
Published: 01 March 2011
上面這篇指引放在 Oxford Academic(牛津學術?不知道有沒有比較統一正式的翻譯). 這個平台收錄牛津大學出版社 (Oxford Univerity Press, OUP) 發行的圖書與電子期刊,

2023-01-02 19:12
另一篇相關文章建議看看. 無症狀之菌尿症評估處置. from uptodate 
下面這段是很久很久以前的筆記. 放在另一篇文章. 

2021-07-30 參考資料 uptodate acute simple cystitis in women
第一線藥物可選下列之一

BAKTAR 比較容易遇到抗藥性. (近期曾感染. 或反覆膀胱炎/尿路感染. 需考慮抗藥性問題)
pivmecillinam 效果較差三個月內若曾服用其中一種抗生素, 再次感染可選擇另一類(避免遇到抗藥性)

First-line antimicrobial options —
The preferred agents for empiric therapy of acute simple cystitis are nitrofurantoin monohydrate/macrocrystals, trimethoprim-sulfamethoxazole, fosfomycin, and, if available, pivmecillinam because of the favorable balance between efficacy and adverse effects (including the risk of selecting for resistant organisms) [1]. None of the first-line agents clearly outweighs the others in terms of the efficacy/adverse effects balance, with the exception that resistance is more likely with trimethoprim-sulfamethoxazole and that pivmecillinam (and possibly fosfomycin) is somewhat less effective; the optimal antimicrobial in one region may be different from that in another depending on resistance prevalence (see 'Resistance trends in E. coli' above). Thus, the choice among them should be individualized based on patient circumstances (allergy, tolerability, expected adherence), local community resistance prevalence, availability, cost, and patient and provider threshold for failure. If the patient has taken one of the agents in the preceding three months, a different one should be selected.

2011-07-18
2010 update. Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases
不建議用FQ作為一線用藥. 
FQ可用於單純的APN. 或者複雜性CYSTITIS. 
https://jamanetwork.com/journals/jama/fullarticle/1832532



 

























Empiric antimicrobial selection for women with acute uncomplicated cystitis

uncomplicated UTI in women. 
如果沒有抗藥性細菌的危險, 不需要做尿液細菌培養, 抗藥性細菌風險包括過去三個月內
1. 尿曾分離出抗藥菌
2. 住養護中心/住院病患/住長照中心 (但肺炎抗藥性細菌與此無關, 與宿主本身因素有關)
3. 曾使用廣效抗生素(FQ/TMP-SMX/ 3rd cefa)
4. 曾在高抗藥細菌盛行區旅行(印度,以色列,西班牙,墨西哥)






























如果以上幾種一線藥物都不適合給(沒進貨?). 可以考慮下面處方

如果不適合給 BETA-LACTAM 可以考慮給 FQ. 




UTI一般給CEFA 500mg Q6H OR BAKTAR 400mg BID

慢性腎病/腎衰竭病患 CKD病患 UTI 可以給ZINNAT(CEFUROXIME) 250mg BID OR CIPROXIN 250mg BID

UPTODATE 裡面提到: 如果抗藥性細菌的機率不高, 可給一線口服抗生素. (nitrofurantoin monohydrate/macrocrystals, trimethoprim-sulfamethoxazole, fosfomycin, or pivmecillinam
Low risk for resistance — For patients who do not have risk factors for an MDR infection (table 1), we typically choose one of the first-line antimicrobial regimens (nitrofurantoin monohydrate/macrocrystals, trimethoprim-sulfamethoxazole, fosfomycin, or pivmecillinam) (algorithm 1). 
For patients who have reasons to avoid all these options (either because of allergies or intolerances or a history of a urinary isolate resistant to these agents within the prior three months), we choose an alternative option. 

First-line antimicrobial options — The preferred agents for empiric therapy of acute uncomplicated cystitis are nitrofurantoin monohydrate/macrocrystals, trimethoprim-sulfamethoxazole, fosfomycin, and, if available, pivmecillinam because of the favorable balance between efficacy and adverse effects (including the risk of selecting for resistant organisms) [1]. None of the first-line agents clearly outweighs the others in terms of the efficacy/adverse effects balance; the optimal antimicrobial in one region may be different from that in another depending on resistance prevalence (see 'Resistance trends in E. coli' above). Thus, the choice among them should be individualized based on patient circumstances (allergy, tolerability, expected adherence), local community resistance prevalence, availability, cost, and patient and provider threshold for failure. If the patient has taken one of the agents in the preceding three months, a different one should be selected.

If all these are appropriate options based on patient circumstances and prior urinary isolates, we suggest nitrofurantoin or trimethoprim-sulfamethoxazole rather than fosfomycin or pivmecillinam. Fosfomycin retains activity against many MDR isolates, but overuse may result in increasing rates of resistance; thus, we reserve its use for suspected MDR infections when there are no other oral options. Pivmecillinam is somewhat less effective but is commonly used in Europe because of a low risk of selection for resistance. 

高尿酸血症之非藥物治療-簡化版

 2026-09-22  食物普林含量表 -A4格式-一張-可直接列印 台北市立聯合醫院中興院區內科個管 筆記: 高尿酸血症/痛風-飲食調整 from uptodate 筆記: 痛風患者飲食建議-Mayo Clinc 尿酸過高 ( 高尿酸血症 ) 的非藥物治療 一般原則 , ...